ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Medicinal seahorses (Hippocampus spp.) for Alzheimer's disease within species conservation framework: an integrated review of ethnopharmacology, bioactivity, bibliometrics, and network pharmacology.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Seahorses (Hippocampus spp.) have been used in traditional Chinese medicine for centuries and are now regarded as underexplored but promising marine resources for modern drug discovery. This review reassesses medicinal seahorses as a potential marine resource for identifying multi-target candidates relevant to Alzheimer's disease (AD) by integrating taxonomy and distribution, conservation, and aquaculture status, ethnomedicinal use, chemical composition, and pharmacology, as well as bibliometric and network-pharmacology analyses. Using published surveys and global databases, we collated records indicating 16 Hippocampus species in Chinese waters and identify five pharmacopeial taxa whose dependence on fragile coastal habitats contrasts with the recent expansion of captive-breeding, tank and pond-based culture, suggesting that regulated aquaculture can supply traceable raw material and alleviate pressure on wild populations. Bibliometric mapping of Web of Science records (1979-2024) shows a shift from aquaculture and conservation towards antioxidant, anti-inflammatory, neuroprotective, and AD-related research. Across the five medicinal species, 329 reported constituents reflect substantial chemical diversity that may contribute to antioxidant, anti-inflammatory, neuroprotective, endocrine and immunomodulatory activities with potential relevance to AD-related pathophysiology. Network-pharmacology analysis links 276 structurally defined compounds to an AD-associated gene module, highlighting a core module centered on APP, JUN and PPARγ as putative mechanistic nodes. This article is based solely on published data and involves no new field collection or experimentation on wild seahorses. We propose that future work should rely on species-verified, aquaculture-derived material, rigorous chemical characterization, and quality control, AD-focused mechanistic and pharmacokinetic studies, and synthetic or biotechnological production of key constituents to support the ethically and ecologically responsible exploration of Hippocampus-based candidates relevant to AD.
Indexed as
Identifiers
41922822What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.